StenoCare A/S

As of June 30, 2026, StenoCare A/S carries a market capitalization of 43.41M, placing it among publicly traded companies globally. Its enterprise value stands at 42.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

StenoCare A/S's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, StenoCare A/S has 43.20M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.70, and the price-to-book ratio stands at 5.05.

As of June 30, 2026, StenoCare A/S trades at an EV/EBITDA multiple of 289.56 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.77 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 42.72M versus a market cap of 43.41M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, StenoCare A/S maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.16, indicating elevated leverage, while an interest coverage ratio of 0.27 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, StenoCare A/S posted a negative return on equity (ROE) of -21.32, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.85, reflecting losses generated across the asset base. The company generates approximately 2.16M in revenue per employee across its workforce of 5.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, StenoCare A/S's stock has declined approximately 49.74% over the past 52 weeks. The 50-day moving average sits at 0.86, while the 200-day moving average is 1.09.

Over the twelve months ended June 30, 2026, StenoCare A/S generated 11.32M in revenue and converted that into -1.18M in net income, yielding earnings per share of -0.03. EBITDA reached 147,540.00, while operating income came in at -677,591.00.

As of June 30, 2026, StenoCare A/S holds 1.74M in cash and equivalents against 1.04M in total debt, resulting in a net debt position of -690,663.00. Total book value stands at 8.59M, with working capital of 1.76M providing operational flexibility.

StenoCare A/S produced -2.35M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -2.35M - equivalent to -0.06 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -5.98 and net profit margin of -10.38 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.20, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to StenoCare A/S shareholders.

StenoCare A/S's most recent stock split took place on January 3, 2025 with a 62:111 split ratio.

As of June 30, 2026, StenoCare A/S has an Altman Z-Score of 10.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.